Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Gender-related differences in patients with psoriatic arthritis2012 · 22 citations
2. 2Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis2018 · 414 citations
3. 3Janus kinases to jakinibs: from basic insights to clinical practice2019 · 155 citations
4. 4Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?2017 · 363 citations
5. 5Toward Treating to Target in Psoriatic Arthritis2015 · 3 citations